News and Updates

ArkBio has received FDA clearance to launch Phase II clinical trials for Ziresovir, a novel RSV antiviral. Learn about this breakthrough treatment's potential.

Aurobindo Pharma faces an FDA warning letter at its Unit-XI facility due to cGMP violations. Discover the impact on drug manufacturing and compliance.

Discover how genomic profiling and precision medicine are transforming pediatric cancer treatment, improving diagnostic accuracy and clinical outcomes.

AI-driven clinical decision support is surging, but is it safe? Explore the critical need for rigorous clinical evidence and oversight in medical AI.

Atrium Therapeutics has opened enrollment for a new PRKAG2 syndrome clinical trial in collaboration with BMS, targeting novel treatments for cardiac disease.

Zipalertinib combined with chemotherapy hit its primary endpoint in a Phase 3 trial, offering new hope for patients with EGFR Exon 20 insertion mutations.

The FDA has granted Fast Track status to Allogene’s TALEN-edited CAR-T therapy for lymphoma, promising a potential shift toward off-the-shelf treatments.

Nektar Therapeutics secures funding to propel Phase 3 trials of rezpegaldesleukin through 2028, targeting advancements in autoimmune disease treatment.

Inhibrx reports Q2 2026 losses while advancing its lead candidate, ozekibart, toward a pivotal FDA review. Get the latest on this major oncology pipeline.

The FDA has greenlit Phase 3 trials for denifanstat, a novel FASN inhibitor targeting moderate to severe acne. Learn how this treatment could redefine care.